Screening for hypermutation-associated MMR defects therefore appears to be of greatest value in recurrent, post-TMZ gliomas, especially MGMT-methylated and/or IDH1 mutant tumors (Fig. 3, Table 3, Additional file 1: Table S2). Here, MGMT is linked to central nervous system cancer.